Literature DB >> 26764009

Influenza A Viruses Expressing Intra- or Intergroup Chimeric Hemagglutinins.

Chi-Jene Chen1, Megan E Ermler1, Gene S Tan1, Florian Krammer2, Peter Palese3, Rong Hai2.   

Abstract

A panel of influenza A viruses expressing chimeric hemagglutinins (cHA) with intragroup or intergroup head/stalk combinations was generated. Viruses were characterized for growth kinetics and preservation of stalk epitopes. With a few notable exceptions, cHA viruses behaved similarly to wild-type viruses and maintained stalk epitopes, which indicated their potential as vaccine candidates to induce stalk-specific antibodies.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Mesh：

Substances：

Year:  2016        PMID： 26764009      PMCID： PMC4794680          DOI： 10.1128/JVI.03060-15

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  20 in total

1.  H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge.

Authors:  Florian Krammer; Irina Margine; Rong Hai; Alexander Flood; Ariana Hirsh; Vadim Tsvetnitsky; Dexiang Chen; Peter Palese
Journal:  J Virol       Date:  2013-12-04       Impact factor: 5.103

2.  Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets.

Authors:  Florian Krammer; Rong Hai; Mark Yondola; Gene S Tan; Victor H Leyva-Grado; Alex B Ryder; Matthew S Miller; John K Rose; Peter Palese; Adolfo García-Sastre; Randy A Albrecht
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

3.  Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses.

Authors:  Teddy John Wohlbold; Raffael Nachbagauer; Irina Margine; Gene S Tan; Ariana Hirsh; Florian Krammer
Journal:  Vaccine       Date:  2015-05-28       Impact factor: 3.641

4.  Persistence of Antibodies to Influenza Hemagglutinin and Neuraminidase Following One or Two Years of Influenza Vaccination.

Authors:  Joshua G Petrie; Suzanne E Ohmit; Emileigh Johnson; Rachel Truscon; Arnold S Monto
Journal:  J Infect Dis       Date:  2015-05-26       Impact factor: 5.226

5.  Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach.

Authors:  Rong Hai; Luis Martínez-Sobrido; Kathryn A Fraser; Juan Ayllon; Adolfo García-Sastre; Peter Palese
Journal:  J Virol       Date:  2008-09-03       Impact factor: 5.103

6.  Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin.

Authors:  Gene S Tan; Peter S Lee; Ryan M B Hoffman; Beryl Mazel-Sanchez; Florian Krammer; Paul E Leon; Andrew B Ward; Ian A Wilson; Peter Palese
Journal:  J Virol       Date:  2014-09-10       Impact factor: 5.103

7.  Disulphide bonds of haemagglutinin of Asian influenza virus.

Authors:  M Waterfield; G Scrace; J Skehel
Journal:  Nature       Date:  1981-01-29       Impact factor: 49.962

8.  Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins.

Authors:  Nicholas S Heaton; David Sachs; Chi-Jene Chen; Rong Hai; Peter Palese
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-25       Impact factor: 11.205

Review 9.  Influenza virus hemagglutinin stalk-based antibodies and vaccines.

Authors:  Florian Krammer; Peter Palese
Journal:  Curr Opin Virol       Date:  2013-08-24       Impact factor: 7.090

10.  Divergent H7 immunogens offer protection from H7N9 virus challenge.

Authors:  Florian Krammer; Randy A Albrecht; Gene S Tan; Irina Margine; Rong Hai; Mirco Schmolke; Jonathan Runstadler; Sarah F Andrews; Patrick C Wilson; Rebecca J Cox; John J Treanor; Adolfo García-Sastre; Peter Palese
Journal:  J Virol       Date:  2014-01-22       Impact factor: 5.103
View more
  25 in total

1.  Development of Influenza B Universal Vaccine Candidates Using the "Mosaic" Hemagglutinin Approach.

Authors:  Weina Sun; Ericka Kirkpatrick; Megan Ermler; Raffael Nachbagauer; Felix Broecker; Florian Krammer; Peter Palese
Journal:  J Virol       Date:  2019-05-29       Impact factor: 5.103

2.  Universal Influenza Virus Vaccines That Target the Conserved Hemagglutinin Stalk and Conserved Sites in the Head Domain.

Authors:  Florian Krammer; Peter Palese
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

3.  Cross protection by inactivated recombinant influenza viruses containing chimeric hemagglutinin conjugates with a conserved neuraminidase or M2 ectodomain epitope.

Authors:  Ki-Hye Kim; Yu-Jin Jung; Youri Lee; Bo Ryoung Park; Judy Oh; Yu-Na Lee; Min-Chul Kim; Subbiah Jeeva; Sang-Moo Kang
Journal:  Virology       Date:  2020-08-22       Impact factor: 3.616

4.  Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in Mice.

Authors:  Angela Choi; Badiaa Bouzya; Klaus-Daniel Cortés Franco; Daniel Stadlbauer; Arvind Rajabhathor; Ronan N Rouxel; Roland Mainil; Marie Van der Wielen; Peter Palese; Adolfo García-Sastre; Bruce L Innis; Florian Krammer; Michael Schotsaert; Corey P Mallett; Raffael Nachbagauer
Journal:  Immunohorizons       Date:  2019-04-01

5.  Increasing the breadth and potency of response to the seasonal influenza virus vaccine by immune complex immunization.

Authors:  Jad Maamary; Taia T Wang; Gene S Tan; Peter Palese; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-05       Impact factor: 11.205

6.  Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model.

Authors:  Megan E Ermler; Ericka Kirkpatrick; Weina Sun; Rong Hai; Fatima Amanat; Veronika Chromikova; Peter Palese; Florian Krammer
Journal:  J Virol       Date:  2017-05-26       Impact factor: 5.103

7.  Broad Hemagglutinin-Specific Memory B Cell Expansion by Seasonal Influenza Virus Infection Reflects Early-Life Imprinting and Adaptation to the Infecting Virus.

Authors:  Brenda L Tesini; Preshetha Kanagaiah; Jiong Wang; Megan Hahn; Jessica L Halliley; Francisco A Chaves; Phuong Q T Nguyen; Aitor Nogales; Marta L DeDiego; Christopher S Anderson; Ali H Ellebedy; Shirin Strohmeier; Florian Krammer; Hongmei Yang; Sanjukta Bandyopadhyay; Rafi Ahmed; John J Treanor; Luis Martinez-Sobrido; Hana Golding; Surender Khurana; Martin S Zand; David J Topham; Mark Y Sangster
Journal:  J Virol       Date:  2019-04-03       Impact factor: 5.103

8.  Immunodominance of Antigenic Site B in the Hemagglutinin of the Current H3N2 Influenza Virus in Humans and Mice.

Authors:  Felix Broecker; Sean T H Liu; Weina Sun; Florian Krammer; Viviana Simon; Peter Palese
Journal:  J Virol       Date:  2018-09-26       Impact factor: 5.103

9.  Activity of human serum antibodies in an influenza virus hemagglutinin stalk-based ADCC reporter assay correlates with activity in a CD107a degranulation assay.

Authors:  Veronika Chromikova; Jessica Tan; Sadaf Aslam; Arvind Rajabhathor; Maria Bermudez-Gonzalez; Juan Ayllon; Viviana Simon; Adolfo García-Sastre; Bruno Salaun; Raffael Nachbagauer; Florian Krammer
Journal:  Vaccine       Date:  2020-01-17       Impact factor: 3.641

10.  Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance.

Authors:  Sean T H Liu; Mohammad Amin Behzadi; Weina Sun; Alec W Freyn; Wen-Chun Liu; Felix Broecker; Randy A Albrecht; Nicole M Bouvier; Viviana Simon; Raffael Nachbagauer; Florian Krammer; Peter Palese
Journal:  J Clin Invest       Date:  2018-10-08       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.